1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Sansure Biotech Inc. Class A

Sansure Biotech Inc. Class A

SSSE:688289
15.58
CNY
-0.33
(-2.07%)
8.34BMarket Cap
Oct 29Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.38
0.51
0.69
8.62
7.67
11.02
1.72
2.49
2.81
- -
Basic EPS, GAAP
-0.02
0.01
0.07
4.74
3.81
3.31
0.62
0.47
0.34
- -
Free Cash Flow per Basic Share
-0.14
-0.04
-0.02
4.59
2.56
3.42
-0.59
-0.25
-0.32
- -
Dividend per Share
0.01
- -
- -
0.55
0.75
1.12
0.68
0.46
0.57
0.3
Book Value per Share
0.71
0.74
1.05
8.02
10.76
12.75
12.24
12.44
12.28
12.07
Tangible Book Value per Share
0.69
0.72
1.02
7.96
10.68
12.6
11.67
11.69
9.83
9.58
Basic Weighted Avg Shares
592
592
531
552
589
585
587
586
585
585
Sales/Revenue/Turnover
225
303
365
4,763
4,515
6,450
1,007
1,458
1,642
- -
Operating Margin (%)
-6.78
4.5
13.52
65.34
56.9
39.27
5.13
12.77
12.82
- -
Depreciation Expense
19
20
21
27
54
89
117
151
212
- -
Net Income, GAAP
-11
7
39
2,617
2,243
1,937
364
276
199
- -
Effective Tax Rate (%)
505.19
36.74
13.16
14.77
14.28
16.37
15.18
13.18
12.09
- -
Profit Margin (%)
-4.74
2.23
10.8
54.94
49.68
30.03
36.12
18.9
12.12
- -
Working Capital
198
214
364
4,392
5,302
5,954
5,030
5,035
4,068
3,979
LT Debt
- -
- -
- -
3
6
14
18
409
978
1,321
Total Equity
379
396
557
4,745
6,381
7,513
7,425
7,346
7,190
7,074
Return on Invested Capital (%)
- -
1.94
8.81
96.88
39.68
27.71
4.8
3.19
2.24
- -
Return on Capital (%)
- -
2.26
8.37
97.59
40.06
27.82
5.08
4.48
3.3
- -
Return on Common Equity (%)
- -
1.74
8.28
98.69
40.36
27.93
4.95
3.82
2.77
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
149
164
204
LT Borrowings
966
1,006
1,312
LT Finance Leases
12
11
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
579
579
579
Market Capitalization
10,956
10,464
8,343

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
5,274
5,161
5,064
Cash, Cash Equivalents & STI
4,125
3,923
3,821
Accounts Receivable, Net
621
668
672
Inventories
414
443
451
Total Current Liabilities
1,206
1,211
1,085
Payables & Accruals
- -
- -
- -
ST Debt
149
164
204
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
9.57%
-2.12%
Free Cash Flow
- -
-31.24%
26.69%
Net Income, GAAP
- -
-32.24%
-27.82%
Sales/Revenue/Turnover
- -
2.13%
12.58%
Total Cash Common Dividend
- -
9.53%
24.32%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
391
326
316
425
1,458
2025
475
393
- -
397
1,642
2026
437
397
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.13
0.07
0.14
0.47
2025
0.16
0.12
- -
0.01
0.34
2026
0.08
0.08
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.2
0.25
0.02
0.46
2025
0.01
0.28
- -
0.02
0.57
2026
0.01
0.28
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Li Zhong Dai
Full Time Employees
2,128
Sector
Health technology
Industry
Medical specialties
Address
No. 680, Lusong Road Changsha HU China 410205
IPO Date
Aug 28, 2020
Website
sansure.com.cn
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Sansure Biotech Inc. (688289.SS) provides integrated in vitro diagnostic solutions centered on molecular diagnostics, genetic testing, and laboratory services, with a focus on reagents, instruments, and third-party medical testing. Founded in 2008 and headquartered in Changsha, China, the company operates through over 40 subsidiaries across China and internationally in markets including the UK, France, the US, Indonesia, the Philippines, and Thailand; it serves over 10,000 hospitals and labs in more than 160 countries. Core products encompass nucleic acid diagnostic kits for respiratory infections such as SARS-CoV-2, influenza A/B, RSV, mycoplasma pneumoniae, and adenovirus; reproductive tract infections including high-risk HPV genotypes (e.g., 13+2, 15HR, 23 types), chlamydia trachomatis, ureaplasma urealyticum, and neisseria gonorrhoeae; bloodborne pathogens like HBV, HCV, and HIV; gastrointestinal infections such as norovirus, rotavirus, and diarrhea bacteria panels; as well as cancer screening, companion diagnostics, and emerging tests for monkeypox, EBV, and HCMV; supporting reagents include magnetic bead-based nucleic acid extraction-purification kits, sample release and storage reagents, and sample diluents; instruments comprise automated extraction systems (e.g., Natch series, S-S13A/S-S14A), real-time PCR systems (SLAN-96P, MA-6000), and POCT platforms (iPonatic II/III); immunoassay offerings feature CLIA and EECL systems. Recent developments include the acquisition of Hygene Biomedicine in January 2025 to bolster its diagnostic portfolio; an additional 10% stake purchase in Hunan Sanway SepSMART Ltd. from Sepset Biosciences Inc. for CNY 5 million in 2024, deepening the 2023 joint venture for sepsis diagnostics commercialization in China; new product approvals such as EBV nucleic acid test kits under EU IVDR and multiplex respiratory virus panels (e.g., influenza, adenovirus) in 2025; and strategic expansions in global R&D partnerships, including ongoing cooperation with QuantuMDx for scalable molecular assays.